News Article | May 15, 2017
— Global In-Vitro Diagnostics Market Information by test types (blood, urine, tissue, others) by technology (includes immunochemistry, molecular diagnostics, others) by application (Cancer, Cardiology, Nephrology, Drug Testing, HIV/AIDS) by end users Laboratories, Hospitals, Academic Institutes) - Forecast to 2027 In vitro diagnostic products are those reagents, instruments, and frameworks planned for use in conclusion of sickness or different conditions, including a determination of the condition of health, with a specific end goal to cure, alleviate, treat, or prevent. Such items are planned for use in the accumulation, preparation, and examination of specimens taken from the human body. Study Objectives of In-Vitro Diagnostics Market: • To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the Global In-Vitro Diagnostics Market • To provide insights about factors affecting the market growth • To Analyze the Global In-Vitro Diagnostics Market based on various factors- price analysis, supply chain analysis, porters five force analysis etc. • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia, and RoW • To provide country level analysis of the market with respect to the current market size and future prospective • To provide country level analysis of the market for segments by test type, by application, by technology by end users and sub-segments. • To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global In-Vitro Diagnostics Market Global In-Vitro Diagnostics Market has been segmented on the basis of applications which consist of Infectious Diseases, Cancer, Cardiology, Nephrology, Drug Testing, HIV/AIDS and others On the basis of test types which include blood, urine, tissue and others. On the basis of technology which includes immunochemistry, molecular diagnostics, self-monitoring blood glucose monitoring, point of care testing, hematology, clinical microbiology. On the basis of end users which includes Laboratories, Hospitals, Academic Institutes and others • Abbott Laboratories, Inc (US) • Roche Diagnostics(Switzerland) • Biomérieux (France) • Ortho Clinical Diagnostics (US) • Johnson & Johnson (US) • Siemens Healthineers (Germany) • Sysmex (japan) • Becton Dickinson (US) • Thermo Fisher Scientific Inc. (US) • Accelerate Diagnostics (US) • Hycor Biomedical (US) • Diagnostic Biosystems (US) • Eurogentec (Belgium) • Orgentec Diagnostics (US) • Immunarray PVT. LTD (US) • Werfen Group (Spain) • Danaher Corporation (US) • Bio-Rad Laboratories INC (US) • Stago Diagnostica (France) • Alere Inc (US) Americas • North America o US o Canada • Latin America Europe • Western Europe o Germany o France o Italy o Spain o U.K o Rest of Western Europe • Eastern Europe Asia– Pacific • Asia o China o India o Japan o South Korea o Rest of Asia • Pacific The Middle East& Africa Request for Table of Content at https://www.marketresearchfuture.com/request-toc/1165 . The report for Global In-Vitro Diagnostics Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions For more information, please visit https://www.marketresearchfuture.com/reports/in-vitro-diagnostics-market
News Article | May 15, 2017
• Growth in the blood group typing market is primarily attributed to the increasing demand for blood and blood products, growing number of road accidents and trauma cases that necessitate blood transfusion, need for blood grouping during prenatal testing, and increasing usage of blood group typing in forensic sciences. • Based on product and service, the market is segmented into consumables, instruments, and services. • The consumables segment is further categorized into antisera reagents, anti-human globulin reagents, red blood cells reagents, and blood bank saline. The blood group typing market is projected to reach USD 3.12 billion by 2021 from USD 1.95 billion in 2016, at a CAGR of 9.8%. Growth in the blood group typing market is primarily attributed to the increasing demand for blood and blood products, growing number of road accidents and trauma cases that necessitate blood transfusion, need for blood grouping during prenatal testing, and increasing usage of blood group typing in forensic sciences. Stringent regulatory standards for blood transfusion are also expected to fuel the growth of the blood group typing market during the forecast period. Based on product and service, the market is segmented into consumables, instruments, and services. The consumables segment is further categorized into antisera reagents, anti-human globulin reagents, red blood cells reagents, and blood bank saline. The consumables segment is expected to grow at the highest CAGR during the forecast period. The increase in blood donation rates and major surgical procedures (including organ transplant procedures) are the key factors driving the growth of this segment. Based on test type, the market is segmented into antibody screening, HLA typing, cross-matching tests, ABO blood tests, and antigen typing. The antibody screening segment is expected to grow at the highest CAGR during the forecast period. The growth of this market segment is primarily driven by the increasing prevalence of chronic disorders and growing demand for the early diagnosis of diseases. Geographically, North America accounted for the largest share of the market in 2016. Growth in the North American segment is primarily driven by the rapid growth in the aging population, availability of reimbursement for several surgeries, and increasing incidence of major disorders. In addition, the high growth potential in the Asian region provides opportunities for players in the market. The major players in the market are Bio-Rad Laboratories, Inc. (U.S.), Grifols, S.A. (Spain), Immucor, Inc. (U.S.), Ortho Clinical Diagnostics, Inc. (U.S.), Quotient, Ltd. (U.S.), ), Novacyt Group (France), BAG Healthcare GmbH (Germany), Rapid Labs (U.K.), Day medical SA (Switzerland), DIAGAST (France), and AXO Science (France). The blood group typing market is segmented based on product and service, technique, test type, end user, and region. Apart from comprehensive geographic & devices analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by players to maintain and increase their shares in the market. This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms, garner greater market shares. Companies purchasing the report can use any one or a combination of the below-mentioned five strategies for strengthening their market shares. The report provides insights on the following pointers: Market Penetration: Comprehensive information on the product portfolios of the top players in the blood group typing market. Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the blood group typing market. Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the blood group typing market. Market Development: Comprehensive information about emerging markets. This report analyzes the market for blood group typing products across geographies. Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the blood group typing market. ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blood-group-typing-market-is-expected-grow-to-312-billion-usd-by-2021-300457898.html
News Article | May 22, 2017
Regulatory updates and key industry feedback from leading IVD manufacturers within the complex and ever-changing landscape. London, United Kingdom, May 22, 2017 --( Nations confirmed to attend include Belgium, France, Germany, Netherlands United Kingdom, UAE & USA. A snapshot of organisations confirmed to join include: Arkray Inc, Berlin Heart A G, BSI, Cytocell Ltd, Dekra, GS1, Immucor, IQ Products, Lifescan (J&J), LNE/G-MED, LRQA, Meridian Bioscience, MET, MHRA, Ortho Clinical Diagnostics, Procorre, Qarad Bvba, Qserve Consultancy, SPD Ltd., Tuv Rheinland, TUV SUD AB, UL International and more. View 2017 Attendee List The agenda will address questions such as: How can IVD manufacturers prepare for the new IVD regulation? How the change in classifications will impact the industry. What are the best strategies and approaches to meeting the requirements for clinical evidence? For those looking to attend there is currently a £100 early bird saving available online. Further information including a detailed agenda and full speaker line-up is available at http://www.in-vitro-diagnostics.co.uk/ein *Source: https://www.visiongain.com/Report/1750/Medical-Devices-Leader-Series-Top-In-Vitro-Diagnostics-(IVD)-Companies-2017-2027 Contact Information: For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: firstname.lastname@example.org About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk London, United Kingdom, May 22, 2017 --( PR.com )-- With just 3 weeks to go, SMi Group have released an attendee list featuring a global audience of regulatory bodies, scientists, medical device experts and industry leaders for In Vitro Diagnostics 2017, set to take place in Central London this June. The international gathering emphasises a growing IVD market which is expected to reach $122.9bn by 2017. *Nations confirmed to attend include Belgium, France, Germany, Netherlands United Kingdom, UAE & USA.A snapshot of organisations confirmed to join include:Arkray Inc, Berlin Heart A G, BSI, Cytocell Ltd, Dekra, GS1, Immucor, IQ Products, Lifescan (J&J), LNE/G-MED, LRQA, Meridian Bioscience, MET, MHRA, Ortho Clinical Diagnostics, Procorre, Qarad Bvba, Qserve Consultancy, SPD Ltd., Tuv Rheinland, TUV SUD AB, UL International and more.View 2017 Attendee ListThe agenda will address questions such as:How can IVD manufacturers prepare for the new IVD regulation?How the change in classifications will impact the industry.What are the best strategies and approaches to meeting the requirements for clinical evidence?For those looking to attend there is currently a £100 early bird saving available online.Further information including a detailed agenda and full speaker line-up is available at http://www.in-vitro-diagnostics.co.uk/ein*Source: https://www.visiongain.com/Report/1750/Medical-Devices-Leader-Series-Top-In-Vitro-Diagnostics-(IVD)-Companies-2017-2027Contact Information:For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: email@example.comAbout SMi Group:Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk Click here to view the list of recent Press Releases from SMi Group
News Article | May 23, 2017
This report, Top 50 Companies in Point-of-Care Diagnostic Testing, profiles the following companies based on their size, product range, innovative capacity and influence in the market: Diagnostic tests performed outside the central laboratory or decentralized testing is generally known as point-of-care (POC). The market is large and companies of various sizes are involved in the development and/or marketing of POC testing. The market is considered evolving with growth opportunity. Developing and developed markets alike have room to grow due to an aging population worldwide. Over the years, the increasing introduction of transportable, portable, and handheld instruments has resulted in the migration of POC testing from the hospital environment to a range of medical environments including the workplace, home, disaster care and most recently, convenience clinics. In addition to profiles of these companies and recent revenue performance where financial information is available, the report provides market sizing and share for the entire POC test market. It also provides market data, including: - Alere - Abbott, Danaher Cepheid and Other Industry Developments - Size and Growth of the Point-of-Care Diagnostics Market, 2016-2021 - Market by Test Segment (Glucose, Pregnancy, FOB, Infectious Disease, Coagulation, Other) - Market by Self-Testing or Professional Testing - Market Share by Vendor - Company Profiling and Revenue Performance - Trends in the Industry Key Topics Covered: 1: Executive Summary - Introduction - Scope and Methodology - Size and Growth Of The Point-Of-Care Market - Trend - Alere and Abbott Merger - Trend - "Star Trek" POC Devices - Trend - Danaher Buys Cepheid - Trend - Retail Clinics - Companies In The POC Market 2: Top 50 Point Of Care Diagnostic Companies - Corporate Profiles - Abaxis, Inc. - Abbott Laboratories - Accriva Diagnostics - Accubiotech Co, Ltd. - Acon Laboratories, Inc - Alere Inc - Arkray - Atlas Genetics Ltd. - Atlas Link Biotech Co., Ltd. - Beckman Coulter, Inc. - Church & Dwight Co. Inc - Danaher Corporation - Dexcom, Inc - Dragerwerk Ag & Co. - Eiken Chemical Co Ltd. - EKF Diagnostics - Enigma Diagnostics, Ltd. - Enterix, Inc - Exact Sciences - Helena Laboratories - Menarini Diagnostics - Meridian Bioscience, Inc - Micronics, Inc - Nova Biomedical, Corp. - Opko Health, Inc - Orasure Technologies, Inc. - Ortho Clinical Diagnostics - Polymer Technologies, Inc (Pts Diagnostics) - Roche Diagnostic Corporation - Samsung Healthcare - Sekisui Diagnostics - Siemens Healthineers - Sysmex Corporation - Trinity Biotech - Veredus Laboratories Ltd 3: POC Testing Market Share And Market Analysis For more information about this report visit http://www.researchandmarkets.com/research/9r93k4/top_50_companies Research and Markets Laura Wood, Senior Manager firstname.lastname@example.org For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/top-50-companies-in-point-of-care-diagnostic-testing-2017-with-size-and-growth-of-the-point-of-care-diagnostics-market-2016-2021---research-and-markets-300462487.html
News Article | April 22, 2017
RARITAN, Nueva Jersey, 22 de abril de 2017 /PRNewswire/ -- Ortho Clinical Diagnostics (en adelante denominada Ortho), empresa que se cuenta entre las primeras del mundo en materia de tecnología de diagnóstico in vitro, ha anunciado hoy que se le ha concedido un premio Edison a la...
News Article | April 22, 2017
Neben dem Edison Award hatte Ortho Anfang des Jahres zwei Global Business Excellence Awards erhalten, mit denen die ORTHO VISION-Plattform für ihre innovative und herausragende Leistung geehrt wurde. Ortho war in diesem Jahr auch mit einem international anerkannten Gold Stevie Award in der Kategorie Global Customer Service für sein Angebot Ortho Care™ ausgezeichnet worden. Dabei handelt es sich um eine umfangreiche Zusammenstellung aus qualitativ hochwertigen Labordiensten und -mitteln, die Ortho-Kunden in Krankenhäusern, Kliniknetzwerken, Blutbanken und unabhängigen Laboren zur Steigerung ihrer allgemeinen Leistungsfähigkeit angeboten wird. Über Ortho Clinical Diagnostics Ortho Clinical Diagnostics gehört zu den weltweit führenden Anbietern in der In-vitro-Diagnostik und bedient klinische Labore und das Fachgebiet der Immunhämatologie auf der ganzen Welt. In Krankenhäusern, Kliniknetzwerken, Blutbanken und Laboren in mehr als 120 Ländern werden Fachkräfte aus dem Gesundheitswesen durch die qualitativ hochwertigen Produkte und Dienstleistungen von Ortho in die Lage versetzt, Entscheidungen für eine Behandlung auf einer besseren Grundlage zu treffen. Die Ortho-Produkte zur Blutgruppenbestimmung helfen der Immunhämatologie-Gemeinschaft dabei sicherzustellen, dass jeder Patient immer das Blut erhält, das sicher ist, zur richtigen Blutgruppe gehört und in der richtigen Menge eingesetzt wird. Ortho stellt klinischen Laboren auf der ganzen Welt intelligente Prüftechniken sowie Instrumente zur Automatisierung, zum Informationsmanagement und für die Interpretation zur Verfügung und hilft ihnen dabei, ihre Einrichtung effizienter und effektiver zu betreiben und die Patientenpflege zu verbessern. Ortho hat sich zum Ziel gesetzt, Leben mithilfe der Diagnostik zu verbessern und zu erhalten, und es verfolgt dieses Ziel, indem es eine neue Vorstellung davon vermittelt, was möglich ist. Das ist es, was Ortho seit mehr als 75 Jahren ausmacht und was Ortho auch zukünftig antreibt. Weitere Informationen erhalten Sie unter www.orthoclinicaldiagnostics.com.
News Article | April 22, 2017
La plateforme ORTHO VISION® intègre les analyseurs ORTHO VISION et ORTHO VISION Max. Conçue pour répondre aux besoins des banques du sang ou des hôpitaux, la plateforme ORTHO VISION contribue à améliorer le flux de travail et soutient la standardisation des systèmes et des processus, permettant aux laboratoires d'accroître leur productivité tout en conservant leur efficience opérationnelle. Le prestigieux prix Edison Award récompense les produits, les services et les solutions qui représentent le meilleur de l'innovation à travers le monde. « Grâce à ses capacités complètes de test, la plateforme ORTHO VISION permet aux laboratoires d'automatiser leurs programmes de test en immuno-hématologie. Cette plateforme aide les laboratoires à délivrer des résultats précis, même face à des pénuries de personnel et à des contraintes de coûts, » a déclaré Heidi Casaletto, vice-présidente de la Médecine transfusionnelle chez Ortho. « Ce prestigieux prix décerné par The Edison Awards récompense notre engagement en faveur de l'innovation et de la démarche consistant à réimaginer ce qui est possible pour nos clients. » Parallèlement à l'Edison Award, Ortho a reçu en début d'année deux prix Global Business Excellence Awards, qui ont récompensé la plateforme ORTHO VISION pour son innovation et son excellence. Cette année également, Ortho a reçu le prix internationalement reconnu Gold Stevie Award dans la catégorie Service clients mondial pour Ortho Care™, ensemble complet de services et ressources de laboratoire de haute qualité fourni aux clients d'Ortho dans les hôpitaux, les réseaux hospitaliers, les banques du sang et les laboratoires indépendants afin qu'ils puissent améliorer leur performance globale. À propos d'Ortho Clinical Diagnostics Ortho Clinical Diagnostics est un leader mondial dans le domaine des diagnostics in vitro, qui dessert les communautés mondiales de laboratoires cliniques et de l'immuno-hématologie. Au sein d'hôpitaux, de réseaux hospitaliers, de banques du sang et de laboratoires dans plus de 120 pays, les produits et services de haute qualité d'Ortho permettent aux professionnels de la santé de prendre des décisions de traitement mieux informées. Destinés à la communauté de l'immuno-hématologie, les produits de typage sanguin d'Ortho contribuent à garantir que chaque patient reçoive un produit sanguin sûr, le groupe sanguin approprié, et l'unité de sang adéquate. Ortho propose des technologies de test sophistiquées, ainsi que des outils d'automatisation, de gestion des informations et d'interprétation aux laboratoires cliniques du monde entier, afin de les aider à opérer de manière plus efficiente et efficace, ainsi qu'à améliorer les soins pour les patients. La mission d'Ortho consiste à améliorer et à sauver des vies grâce aux diagnostics, et la société y parvient en réimaginant ce qui est possible. C'est ce qui définit et fait avancer Ortho depuis plus de 75 ans. Pour en savoir plus, rendez-vous sur www.orthoclinicaldiagnostics.com.
News Article | February 21, 2017
Dublin, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Therapeutic Drug Monitoring - Technologies, Markets, and Companies" to their offering. This report deals with therapeutic drug monitoring, a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug levels in the blood to individually adjust the dose of drugs for improving outcome. TDM is viewed as a component of personalized medicine that interacts with several other disciplines including pharmacokinetics and pharmacogenetics. One chapter is devoted to monitoring of drugs of abuse (DoA). Various technologies used for well-known DoA are described. A section on drug abuse describes methods of detection of performance-enhancing drugs. TDM market is analyzed from 2015 to 2025 according to technologies as well as geographical distribution. Global market for DoA testing was also analyzed from 2016 to 2026 and divided according to the area of application. Unmet needs and strategies for development of markets for TDM are discussed. The report contains profiles of 27 companies involved in developing tests and equipment for drug monitoring along with their collaborations. The text is supplemented with 18 tables, 6 figures and 190 selected references from literature. Benefits of this report: - Up-to-date one-stop information on therapeutic drug monitoring - Description of 27 companies involved with their collaborations in this area - Market analysis 2016-2026/ - Market values in major regions - Strategies for developing markets for therapeutic drug monitoring - A selected bibliography of 190 publications - Text is supplemented by 18 tables and 6 figures Who should read this report? - Biotechnology companies developing assays and equipment for drug monitoring - Reference laboratories providing drug monitoring services - Pharmaceutical companies interested in companion tests for monitoring their drugs - Clinical pharmacologists interested in integrating therapeutic drug monitoring with pharmacogenetics for development of personalized medicine Key Topics Covered: Executive Summary 1. Introduction Definitions Historical Landmarks in the development of TDM Pharmacology relevant to TDM Pharmacokinetics Pharmacodynamics Pharmacogenetics Pharmacogenomics Pharmacoproteomics Drug receptors Protein binding Therapeutic range of a drug Variables that affect TDM Indications for TDM Multidisciplinary nature of TDM 2. Technologies for TDM Introduction Sample preparation Proteomic technologies Mass spectrometry Liquid chromatography MS Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Combining capillary electrophoresis with MS Gas-liquid chromatography Tissue imaging mass spectrometry New trends in sample preparation Pressure Cycling Technology Desorption electrospray ionization imaging High Performance Liquid Chromatography (HPLC) Ultra performance LC TDM using dry blood spots Analysis of dried blood spots for drugs using DESI Quantitative analysis of drugs in dried blood spot by paper spray MS Immunoassays Enzyme-linked immunosorbent assay Cloned Enzyme Donor Immunoassay Enzyme Multiplied Immunoassay Technique Fluorescence Polarization Immunoassay Particle Enhanced Turbidimetric Inhibition Immunoassay Radioimmunometric assays Biosensors Nanosensors Biochips & Microarrays Introduction Microchip capillary electrophoresis Phototransistor biochip biosensor Microchip-based fluorescence polarization immunoassay for TDM Cellular microarrays Microfluidics for TDM Lab-on-a-chip Micronics' microfluidic technology Rheonix CARD technology Nano-interface in a microfluidic chip Levitation of nanofluidic drops with physical forces Nanoarrays Nanobiotechology NanoDx Biomarkers Applications of biomarkers in drug safety studies Genomic technologies for toxicology biomarkers Proteomic technologies for toxicology biomarkers Metabonomic technologies for toxicology biomarkers Integration of genomic and metabonomic data to develop toxicity biomarkers Toxicology studies based on biomarkers Biomarkers of hepatotoxicity Biomarkers of nephrotoxicity Cardiotoxicity Neurotoxicity Biomarkers in clinical trials Molecular diagnostics 3. Drug Monitoring Instruments Introduction Description of important instruments AB SCIEX instruments AB SCIEX LC/MS/MS Abbott instruments ARCHITECT c16000 ARCHITECT c4000 ARCHITECT c8000 ARCHITECT ci16200 Integrated System ARCHITECT ci4100 Integrated System ARCHITECT ci8200 integrated with the ARCHITECT i2000SR ARCHITECT i1000SR ARCHITECT i4000SR AxSYM Agilent's 6400 Series Triple Quadrupole LC/MS Alfa Wassermann's ACE Alera AMS Diagnostics' LIASYS Awareness Technology's STAT FAX 4500 Beckman Coulter instruments Beckman Coulter Unicel Series AU5800 automated chemistry systems AU480 Binding Site ESP600 bioMerieux Mini Vidas Carolina BioLis 24i Chromsystems' HPLC instruments Grifols Triturus ABX Pentra 400 Medica EasyRA Nova Biomedical Critical Care Xpress Ortho Clinical Diagnostics' VITROS® family of systems Immunodiagnostic systems Randox intruments Randox RX Imola Roche instruments Cobas® 8000 COBAS INTEGRA® Systems Siemens instruments ADVIA 1200 ADVIA Centaur XP immunoassay system EMIT® II Plus Syva® Viva® Drug Testing Systems Dimension® Xpand® Plus Integrated Chemistry System Thermo Scientific instruments Indiko Tosoh AIA-Series 4. Applications of TDM Introduction Pharmaceutical research and drug development Clinical trials Computerized clinical decision support systems for TDM and dosing Medication-related interferences with measurements of catecholamines Polymorphisms of genes affecting drug metabolism TDM for drug safety TDM in special groups The aged Children Pregnancy TDM of prophylactic therapy Monitoring of vitamin D levels Monitoring of RBC folic acid levels during pregancy Personalized medicine Role of TDM in personalized medicine Applications according to various conditions Anesthesia and critical care Optimizing antimicrobial dosing for critically ill patients TDM monitoring of thiopental continuous infusion in critical care Role of TDM in critical care cardiac patients. Cancer Epilepsy Personalized approach to use of AEDs Infections Virus infections Fungal infections Pain management Role of TDM in pain management Monitoring of analgesic drugs in urine samples AEDs as analgesics Triptans for migraine Psychiatric disorders Guidelines for use of TDM in psychiatric patients TDM of psychotropic drugs Transplantation TDM of Tacrolismus in transplantation TDM of cyclosporine A in transplantation Monitoring of immunosuppression with mycophenolate mofetil Emergency toxicology Future prospects of TDM 5. Drugs Requiring Monitoring Introduction Antiepileptics Carbamazepine TDM of carbamazepine Gabapentin Lacosamide Lamotrigine TDM of lamotrigine Levetiracetam TDM of levetiracetam Phenobarbital TDM of phenobarbital Phenytoin TDM of phenytoin Primidone TDM of primidone Topiramate TDM of topiramate Valproic acid TDM of valproic acid TDM of multiple antiepileptic drugs in plasma/serum Antimicrobials Antibiotics Amikacin Anti-tuberculosis drugs Chloramphenicol Gentamicin Tobramycin Vancomycin Norvancomycin Antiviral agents Anti-HIV drugs Antifungal agents Voriconazole Antidepressants TDM of selective serotonin reuptake inhibitors Antipsychotics Aripiprazole Quetiapine TDM of risperidone TDM of AEDs in psychiatric disorders TDM of multiple drugs in psychiatry Bronchodilators Theophylline Cardiovascular drugs Antiarrhythmic drugs Anticoagulants Dabigatran Antihypertensive drugs ß-blockers Cardiotonic drugs Digoxin TDM of statins for hypercholesterolemia Chemotherapy for cancer TDM of 5-FU TDM of Methotrexate TDM of imitanib Drugs used for treatment of Alzheimer disease Donepezil Galantamine Memantine Drugs used for treatment of Parkinson disease Monitoring of levodopa and carbidopa therapy Catechol-O-methyltransferase inhibitors Drugs for treatment of attention-deficit hyperactivity disorder Atomoxetine Methylphenidate Hypnotic-sedative drugs Benzodiazepines Propofol Immunosuppressive drugs TDM of mycophenolic acid for the treatment of lupus nephritis Steroids Prednisone Miscellaneous drugs Azathioprine Sildenafil 6. Monitoring of Biological Therapies Introduction Cell therapy In vivo tracking of cells Molecular imaging for tracking cells MRI technologies for tracking cells Superparamagnetic iron oxide nanoparticles as MRI contrast agents Visualization of gene expression in vivo by MRI Gene therapy Application of molecular diagnostic methods in gene therapy Use of PCR to study biodistribution of gene therapy vector PCR for verification of the transcription of DNA In situ PCR for direct quantification of gene transfer into cells Detection of retroviruses by reverse transcriptase (RT)-PCR Confirmation of viral vector integration Monitoring of gene expression Monitoring of gene expression by green fluorescent protein Monitoring in vivo gene expression by molecular imaging Monoclonal antibodies Natalizumab 7. Monitoring of Drug Abuse Introduction Tests used for detection of drug abuse Forensic applications of detection of illicit drugs in fingerprints by MALDI MS MS for doping control Randox assays for DoA Drugs of Abuse Array V Urine drug testing TDM of drugs for treatment of substance abuse-related disorders Drug testing to monitor treatment of drug abuse Minimum requirement for drug testing in patients Analgesic abuse ?-blockers as doping agents Detection of ß-blockers in urine Chronic alcohol abuse Cocaine CEDIA for cocaine in human serum Detection of cocaine molecules by nanoparticle-labeled aptasensors Infrared spectroscopy for detection of cocaine in saliva Marijuana Use of marijuana and synthetic cannabinoids Detection of cannabinoids ELISA for detection of synthetic cannabinoids Drug abuse for performance enhancement in sports Historical aspects of drug abuse in sports Drugs used by athletes for performance enhancement Techniques used for detection of drug abuse by athletes Mass spectrometry for detection of peptide hormones miRNAs for the detection of erythropoiesis-stimulating agents Detection of anabolic steroids Body fluids and tissues used for detection of drug abuse in sports Urine drug testing Spray (sweat) drug test kits Hair drug testing Gene doping in sports Gene transfer methods used for enhancing physical performance Misuse of cell therapy in sport Challenges of detecting genetic manipulations in athletes Drug abuse testing in race horses Limitations and future prospects Role of pharmaceutical industry in anti-doping testing 8. Markets for TDM Introduction Methods for market estimation and future forecasts Markets for TDM tests Markets for TDM and DoA testing equipment Geographical distribution of markets for TDM tests Drivers for growth of TDM markets Markets for DoA testing Unmet needs in TDM Cost-benefit studies Simplifying assays and reducing time and cost Strategies for developing markets Physician education Supporting research on TDM Biomarker patents for drug monitoring 9. Companies Profiles of companies Collaborations 10. References For more information about this report visit http://www.researchandmarkets.com/research/g4tq2x/therapeutic_drug
News Article | February 28, 2017
Le programme d'appui et de service Ortho Care™ est sacré meilleur de sa catégorie pour les hôpitaux, les réseaux hospitaliers, les banques de sang et les laboratoires RARITAN, New Jersey, 28 février 2017 /PRNewswire/ -- Ortho Clinical Diagnostics (Ortho), un leader mondial du...
News Article | January 12, 2017
Ortho Clinical Diagnostics' Ortho Connect V2.0 middleware solution is CE Marked, signifying conformity with all EU regulation. The product is a comprehensive, integrated and customizable intermediary software that streamlines laboratory operations, allowing lab professionals to manage multiple instruments from a single console and define rules specific to their needs. It also enables immunohematology analyzers, which test blood for transfusion compatibility, to connect to a hospital’s Laboratory Information Systems (LIS) to exchange data and simplify processes. The software is now available for purchase in Europe and other countries that accept the CE Mark. The software strengthens Ortho’s transfusion medicine portfolio capabilities. It was developed to address the myriad demands placed on lab managers, whose limited staff have diverse skill sets and are asked to serve an expanding array of health networks. With cost containment and increased haemovigilance top of mind, lab managers need to consolidate and standardize their instruments while optimizing both automation and workflow. The software provides labs with highly customizable middleware that allows them to automate results validation and quality-check testing requirements; simplify processes such as data management and regulatory requirements that laboratory information systems (LIS) cannot do alone; and further enhance efficiency through remote connectivity. Through its functionality, the software works to support a lab’s ability to improve safety and lab efficiency at every step of the testing process. The system is highly configurable, allowing labs to choose from more than 40 rules to meet their specific demands. Pre-process conversion rules can automatically perform specific tests and post-processing reflex testing can be defined to deliver required results. By automating results validation and QC testing, it simplifies processes, ensures compliance and increases result traceability. The software works seamlessly with the comprehensive, integrated and scalable suite of products developed for Immunohematology labs.